Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27394078 | 1.00 | GPR119 (0.58) | GPR119PIK3CDPIK3CAUSP30PIK3CB | |
| SCHEMBL16980514 | 1.00 | GPR119 (0.58) | GPR119PIK3CDPIK3CAUSP30PIK3CB | |
| SCHEMBL16973079 | 0.93 | GPR119 (0.51) | GPR119PIK3CDPIK3CAUSP30 | |
| SCHEMBL3180265 | 0.93 | GPR119 (0.66) | GPR119 | |
| SCHEMBL3398165 | 0.91 | GPR119 (0.51) | GPR119PIK3CDPIK3CAUSP30 | |
| SCHEMBL21887083 | 0.87 | GPR119 (0.59) | GPR119PIK3CDPIK3CA | |
| SCHEMBL26774179 | 0.87 | GPR119 (0.59) | GPR119PIK3CDPIK3CA | |
| SCHEMBL20234855 | 0.87 | GPR119 (0.59) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL26774174 | 0.87 | GPR119 (0.59) | GPR119PIK3CDPIK3CA | |
| SCHEMBL22825652 | 0.86 | GPR119 (0.58) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| EP-2247591-A1 | PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | GPR119 1569/4885PIK3CD 400/4885PIK3CA 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.